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TopBP1 serves as an activator of the ATR-ATRIP complex in
response to the presence of incompletely replicated or damaged
DNA. This process involves binding of ATR to the ATR-activat-
ingdomainofTopBP1,which is locatedbetweenBRCTdomains
VI and VII. TopBP1 displays increased binding to ATR-ATRIP
in Xenopus egg extracts containing checkpoint-inducing DNA
templates. We show that an N-terminal region of TopBP1 con-
taining BRCT repeats I-II is essential for this checkpoint-stim-
ulated binding ofTopBP1 toATR-ATRIP.TheBRCT I-II region
of TopBP1 also binds specifically to the Rad9-Hus1-Rad1
(9-1-1) complex inXenopus egg extracts. This binding occurs via
the C-terminal domain of Rad9 and depends upon phosphoryl-
ation of its Ser-373 residue. Egg extracts containing either a
mutant of TopBP1 lacking the BRCT I-II repeats or a mutant of
Rad9 with an alanine substitution at Ser-373 are defective in
checkpoint regulation. Furthermore, an isolated C-terminal
fragment from Rad9 is an effective inhibitor of checkpoint sig-
naling in egg extracts. These findings suggest that interaction of
the 9-1-1 complex with the BRCT I-II region of TopBP1 is nec-
essary for binding ofATR-ATRIP to theATR-activating domain
of TopBP1 and the ensuing activation of ATR.
Eukaryotic cells possess checkpoint regulatory mechanisms
that are essential for safeguarding of the genome (1–3). Com-
ponents of these biochemical systems probe chromosomes for
the presence of damaged or partially replicated DNA. ATM2
and ATR, which are both phosphoinositide kinase-related pro-
tein kinases, operate near the apex of checkpoint pathways (1).
ATM is involved mainly in the detection of double-stranded
DNA breaks (4). ATR has a discrete role in the detection of
stalled DNA replication forks, but it also functions in double-
stranded DNA breaks-triggered responses (1, 4, 5). A critical
function of ATR involves activation of the downstream check-
point effector kinase Chk1. In turn, Chk1 prohibits cell cycle pro-
gression by phosphorylating downstream cell cycle control pro-
teins such asCdc25 andWee1 as long as damagedor incompletely
replicated DNA is present in the cell (6).
TheATR-dependent activation of Chk1 is an elaborate proc-
ess that involves numerous additional factors (3, 5, 7). ATR
itself possesses a tightly bound and indispensable subunit called
ATRIP (8). Our laboratory has demonstrated that a protein
known as TopBP1 functions as a direct activator of ATR-
ATRIP (9). Once ATR-ATRIP becomes activated by TopBP1, it
requires the assistance of the mediator protein Claspin to carry
out the final activating phosphorylations of Chk1 (10–13).
Other factors that are important in the pathway leading to the
activation of Chk1 include checkpoint clamp loader and clamp
complexes (3). In particular, a clamp loader consisting of Rad17
and the four small replication factor C subunits catalyzes the
deposition of a trimeric checkpoint clamp onto checkpoint-
triggering locations in chromosomes. This clamp, which is
composed of Rad9, Hus1, and Rad1, is commonly referred to as
the 9-1-1 complex (14). It is thought that this complex is loaded
onto recessed DNA ends, which would be present at both
stalled DNA replication forks and double-stranded DNA
breaks that have undergone resection (15–19).
We have been investigating how the action of TopBP1 as an
ATR-activating protein might be regulated during checkpoint
responses. Recently, our laboratory reported that TopBP1 dis-
plays increased binding to ATR-ATRIP in the presence of
checkpoint-triggering DNA templates in Xenopus egg extracts
(20). Here we show that this regulated binding involves an
N-terminal domain of TopBP1 containing its first two BRCT
repeats. This region was not previously known to be important
for the checkpoint-regulatory function ofTopBP1 (21, 22). This
segment does not bind directly to ATR-ATRIP, but does inter-
act well with the 9-1-1 complex via the C-terminal region of the
Rad9 protein. This interaction is necessary for normal activa-
tion of Chk1 inXenopus egg extracts. Thus, interaction of Rad9
with an essential region of the ATR-activating protein TopBP1
is critical for the initiation of checkpoint signaling.
EXPERIMENTAL PROCEDURES
Xenopus Egg Extracts—Extracts from Xenopus egg were pre-
pared as described previously (23). TheDNA replication check-
point was induced by addition of aphidicolin (50 g/ml) to
interphase egg extracts containing demembranated sperm
nuclei (4000/l) and cycloheximide (100g/ml). Alternatively,
checkpoint responses were triggered by addition of 50 g/ml
(dA)70-(dT)70 to egg extracts supplemented with 3 M tauto-
mycin (10). Methods for isolation of total nuclear and chroma-
tin fractions are described previously (24).
Antibodies and Immunodepletion—Antibodies against
Xchk1, Xhus1, Xmcm7, Claspin, phospho-Ser-864 of Claspin,
Xatr, and XtopBP1 were previously described (9, 10, 23–25).
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Antisera against Xrad9 and Xrad1 were kindly provided by Dr.
Howard Lindsay (Lancaster University, Lancaster, UK). Anti-
GST and anti-phospho-Ser-344 of Xchk1 antibodies were pur-
chased from Santa Cruz Biotechnology and Cell Signaling
Technology, respectively. Control IgG was obtained from
Zymed Laboratories Inc. For immunodepletion of the 9-1-1
complex, affinity-purified anti-Xhus1 antibodies (150 g total)
were bound to recombinant protein A-Sepharose (GE Health-
care) and incubatedwith egg extract (100l) in three successive
rounds. XtopBP1 was immunodepleted by published methods
(9).
Recombinant Proteins—DNA constructs encoding various
deletionmutants ofHF-XtopBP1 lacking the indicated residues
(I-II, 106–282; III, 360–428; IV-V, 588–710; VI, 760–
1014; AAD, 993–1196; and VII-VIII, 1227–1485) were pro-
duced using the QuikChange kit (Stratagene) with pFastBac-
HF-XtopBP1 as template (20). HF-XtopBP1 contains both
hemagglutinin andHis6 tags at the N-terminal end and a FLAG
tag at the C-terminal end. In the case of XtopBP1 fragments
containing the N-terminal region (760–1485), C-terminal
region (1–757), and BRCT domains I-II (360–1485) and
III-VI (2–312 and 1006–1485), sequences encoding the
indicated amino acids were removed by PCR-based methods.
All recombinant versions of XtopBP1 were designed to contain
the region with its putative nuclear localization sequence
(amino acids 1495–1500) and were observed to enter the
nucleus normally (data not shown). The sequence encoding
Xrad9was subcloned into the pFastBac-HTb vector to generate
the His6-Xrad9 construct. Serine 373 of Xrad9 was changed
into alanine (Xrad9-S373A) with the QuikChange kit. Recom-
binant baculoviruses were produced with Bac-to-Bac system
(Invitrogen). Expressed proteins were purified with nickel-aga-
rose beads (10). For preparation of recombinant Xenopus 9-1-1
complex, baculoviruses encoding untagged Xhus1 and Xrad1
(kindly provided by Dr. Karlene Cimprich, Stanford University,
CA) and His6-Xrad9 were used to coinfect Sf9 insect cells. The
complexes were purified as described (26) and analyzed by
SDS-PAGE and immunoblotting. Sequences encoding various
segments from the C-terminal region of Xrad9 were amplified
by PCR and inserted into the pGEX-4T3 vector (GE Health-
care). Unless indicated otherwise, the construct containing res-
idues 258–377 is referred to as GST-Xrad9C. GST fusion pro-
teins were expressed in Escherichia coli BL21 pLysS cells and
purified with glutathione-agarose beads. For inhibition of the
phosphorylation of Xchk1 in egg extracts, these peptides were
added up to a final concentration of 0.1 mg/ml. 35S-Labeled
Xchk1 was synthesized in vitro with TNT reticulocyte lysate
system (Promega).
Protein Binding Assays—HF-XtopBP1 proteins (2 g) were
incubated in 100 l of interphase egg extract for 90 min and
recovered with anti-FLAG antibody beads (Sigma). In some
cases, anti-FLAG antibodies were bound to protein Gmagnetic
beads (Dynal Biotech). For GST-Xrad9 fragments, proteins (5
g each) were incubated in 100 l of interphase egg extract for
90 min and recovered with glutathione beads as described pre-
viously (10). Treatments with  protein phosphatase (20 units/
l; New England Biolabs) were carried out on GST-Xrad9C
bound to glutathione-agarose beads for 30 min at room tem-
perature in the buffer provided by the manufacturer.
Phosphopeptide Mapping—Wild-type and S373A GST-
Xrad9C were incubated in egg extracts supplemented with
[-32P]ATP for 90min and purified as described above. Labeled
proteins were excised from SDS gels and digested with trypsin.
Phosphopeptide mapping was carried out as before (27).
RESULTS
XtopBP1 Associates with the C-terminal Domain of Xrad9 in
Frog Egg Extracts—The C-terminal domain of Rad9 is impor-
tant for checkpoint signaling in yeast and vertebrates (26,
28–30). To examine a potential functional relationship
between this region of Rad9 and TopBP1 in Xenopus egg
extracts, we prepared a GST fusion protein containing the
C-terminal 120 amino acids ofXenopus Rad9 (Xrad9) (residues
258–377).We incubated this fusion protein (hereafter referred
to as GST-Xrad9C) in egg extracts, subsequently recovered
the protein with glutathione-agarose beads, and performed
immunoblotting with antibodies against Xenopus TopBP1
(XtopBP1). As shown in Fig. 1A, we could readily detect binding
of endogenous XtopBP1 from egg extracts to exogenously
added GST-Xrad9C. There was no binding of XtopBP1 to glu-
tathione beads in extractswithout addedGST-Xrad9C. In these
experiments, we observed a large upward mobility shift of
GST-Xrad9C in SDS gels as a result of incubation in egg
extracts. This shift appears to represent phosphorylation
because it can be abolished by treatment with  protein
phosphatase. Furthermore, this phosphatase treatment
caused dissociation of XtopBP1 that had originally bound to
GST-Xrad9C in egg extracts. This observation suggests that
the interaction between XtopBP1 and GST-Xrad9C depends
upon phosphorylation.
To examine which portion of Xrad9C is important for bind-
ing to XtopBP1, we prepared a variety of deletion mutants. As
depicted in Fig. 1B, removal of up to 80 amino acids from the
N-terminal end of the fragment did not affect binding signifi-
cantly. However, removal of 20 additional residues (to yield the
358–377 fragment) did completely abrogate interaction with
XtopBP1. Moreover, deletion of the last 20 amino acids from
the opposite C-terminal end of the 258–377 fragment also
eliminated binding to XtopBP1 (Fig. 1, C and D). Taken
together, these results indicate that the last 20 amino acids of
Xrad9 are necessary for binding of XtopBP1 in egg extracts, but
that a somewhat larger fragment containing up to 40 C-termi-
nal amino acids is sufficient. These findings are consistent with
studies in human cells (31).
The C-terminal domain of Rad9 is highly phosphorylated in
yeast and vertebrates (28–30).Within the last 20 amino acids of
human Rad9, Ser-387 is constitutively phosphorylated during
the cell cycle in tissue culture cells and is required for binding of
TopBP1 (29). Phosphorylation of human Rad9 on Ser-387 does
not require the presence of a checkpoint-inducing DNA lesion.
This residue is highly conserved in vertebrates and corresponds
to Ser-373 in Xrad9 (see Fig. 1C). In this region of fission yeast
Rad9, bothThr-412 and Ser-423 undergo phosphorylation (30).
Phosphorylation of Thr-412 has been implicated in the binding
of Rad9 to Cut5 in fission yeast. To test whether phosphoryla-
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tion of Ser-373 is necessary for binding of Xrad9 to XtopBP1 in
egg extracts, wemutated this residue to alanine in the context of
the GST-Xrad9C protein. The resulting S373Amutant had vir-
tually no ability to interact with XtopBP1 (Fig. 1D). We verified
by tryptic phosphopeptide mapping that Ser-373 of GST-
Xrad9C (containing residues 258–377) undergoes phosphoryl-
ation in egg extracts (Fig. 1E).
Role of Ser-373 from Xrad9 in Checkpoint Regulation—We
proceeded to assess whether Ser-373 of Xrad9 is involved in
checkpoint signaling in egg extracts. For this purpose, we
immunodepleted the endogenous 9-1-1 complex from egg
extracts with anti-Xhus1 antibodies and replaced it with
recombinant 9-1-1 complexes containing either wild-type or
S373A Xrad9 (Fig. 2, A and B). In parallel, we prepared mock-
depleted extracts with control antibodies. We added aphidico-
lin and demembranated Xenopus sperm nuclei to the extracts
to create chromatin with DNA rep-
lication blockages. Finally, we mon-
itored activation of the DNA repli-
cation checkpoint by observing
phosphorylation of 35S-Xchk1 in
nuclear fractions from the extracts.
As shown in Fig. 2C, removal of the
9-1-1 complex from egg extracts
resulted in a significant reduction of
the aphidicolin-induced phospho-
rylation of Xchk1, consistent with
previous results (26, 32). Phospho-
rylation could be restored by the
addition of recombinant wild-type
9-1-1 complex, but not a mutant
complex with the S373AXrad9 sub-
unit. Therefore, Ser-373 of Xrad9
appears to be functionally impor-
tant for checkpoint signaling.
Xrad9 Interacts with the BRCT
I-II Region of XtopBP1—Next,
we examined which portion of
XtopBP1 was necessary for interac-
tion with Xrad9. For this question,
we prepared deletion mutants of
recombinant, full-length XtopBP1
(HF-XtopBP1) lacking certain
BRCT domains (see Fig. 3A). In par-
ticular, we removed regions that
contained BRCT domains I-II, III,
IV-V, VI, and VII-VIII. In addition,
we prepared a deletion mutant of
XtopBP1 that lacks its ATR-activat-
ing domain (AAD) (9). We incu-
bated wild-type HF-XtopBP1 and
the various deletion mutants in
Xenopus egg extracts, recovered the
proteins with anti-FLAG antibody
beads, and then performed immu-
noblotting with anti-Xrad9 anti-
bodies. Typically, all of the recombi-
nant XtopBP1 proteins with the
exception of the one lacking BRCTdomains I-II could associate
with endogenous Xrad9 in egg extracts (Fig. 3B). Likewise, we
observed the same binding pattern for endogenous Xhus1,
another component of the 9-1-1 complex. Interestingly, we
could also detect binding of endogenous Xrad17 (the large sub-
unit of theXenopusRad17-replication factorC clamp loader) to
all of the constructs that bound the 9-1-1 components. In par-
allel, we also asked whether the isolatedGST-Xrad9C fragment
displayed similar binding properties. We observed that the
C-terminal domain of Xrad9 could not associate with the I-II
mutant of XtopBP1, whereas it bound readily to wild-type,
AAD, and III versions of XtopBP1 under the same condi-
tions (Fig. 3C).
We also investigated, which regions of XtopBP1 were suffi-
cient for binding of Xrad9. For these experiments, we used
FLAG-tagged fragments of XtopBP1 containing approximately
FIGURE 1. XtopBP1 associates with the C-terminal domain of Xrad9 in a phosphorylation-dependent
manner. A, Xenopus egg extracts (lanes 1, 3, and 4) and control buffer (lane 2) were incubated in the absence
(lane 1) or presence (lanes 2–4) of GST-Xrad9C. Next, the samples were incubated with glutathione-agarose
beads, and the beadswere later retrieved andwashed. For lanes 3 and 4, the beadswere incubated oncemore
in the absence (lane 3) or presence (lane 4) of  protein phosphatase. These beadswere thenwashed again. All
sampleswere subjected to SDS-PAGE and immunoblottedwith anti-XtopBP1 and anti-GST antibodies.Asterisk
and arrow denote unshifted and shifted forms of GST-Xrad9C, respectively. B, GST fusion proteins containing
the indicated amino acids of Xrad9 were subjected directly to SDS-PAGE (lanes 1, 3, 5, 7, and 9) or incubated in
Xenopus egg extracts (lanes 2, 4, 6, 8, and 10). Subsequently, glutathione-agarose beads were incubated in the
egg extracts, retrieved, and subjected to SDS-PAGE. All samples were immunoblotted with anti-XtopBP1 and
anti-GST antibodies. C, sequence alignment of the C-terminal 40 amino acids of Xrad9 with the C-terminal
regions of human, mouse, and Schizosaccharomyces pombe Rad9. Arrow indicates Ser-373 of Xrad9. Asterisks
denote Thr-412 and Ser-423 of S. pombe Rad9. D, the indicated versions of GST-Xrad9 were subjected to
SDS-PAGE directly (lanes 1, 3, and 5) or incubated in egg extracts and later retrieved with glutathione beads
(lanes 2, 4, and 6). Samples were immunoblotted for XtopBP1 and GST. E, Wild-type and S373A versions of
GST-Xrad9C (residues 258–377) were incubated in egg extracts in the presence of [-32P]ATP, isolated with
glutathione-agarose beads, and processed for tryptic phosphopeptide mapping as described under “Experi-
mental Procedures.” The dotted circle demarcates the position of the Ser-373-containing peptide. Origins are
indicated by a dot.
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its N- and C-terminal halves. In addition, we prepared smaller
recombinant fragments containing BRCT domains I-II or III-
VI. Consistent with the results described above, the N-terminal
domain of XtopBP1 bound well to endogenous Xrad9 and
Xhus1, whereas there was no binding of the C-terminal domain
(Fig. 3D). Furthermore, a fragment of XtopBP1 containing
BRCT domains I-II, but not one comprised of domains III-VI,
could associate with endogenous Xrad9 and Xhus1 from egg
extracts. Finally, in reciprocal binding experiments, we found
that GST-Xrad9C could pull down both the N-terminal half of
XtopBP1 and the BRCT I-II fragment, but not the C-terminal
half of the protein or the BRCT III-VI fragment (Fig. 3E). Taken
together, these results indicate that the BRCT I-II region of
XtopBP1 is both necessary and sufficient for binding to the
C-terminal domain of Xrad9.
The BRCT I-II Domain of XtopBP1 Is Essential for Checkpoint
Signaling in Egg Extracts—We turned to the issue of whether
the BRCT I-II domain of XtopBP1 is required for checkpoint
signaling. To address this question, we immunodepleted
endogenous XtopBP1 from egg extracts with anti-XtopBP1
antibodies and replaced itwith eitherwild-type,AAD, orI-II
versions of HF-XtopBP1 (Fig. 4A). Next, we added sperm chro-
matin and aphidicolin to the extracts and then examined phos-
phorylation of Xchk1 in nuclear fractions (Fig. 4B). As
expected, there was no phosphorylation of Xchk1 in XtopBP1-
depleted extracts (9, 21, 22, 33). Consistent with previous
reports, we could restore this phosphorylation by adding back
wild-type full-length HF-XtopBP1 (9, 21, 22). However, we
could not rescue this defect with AAD mutant of
HF-XtopBP1, which reflected the fact that the AAD was
required for the activation of ATR. Significantly, we found that
theI-II mutant was also unable to support phosphorylation of
Xchk1 even though it contained an intact AAD. This observa-
tion suggests that the BRCT I-II region somehow regulates the
function of the AAD. To corroborate this finding further, we
used the model DNA template (dA)70-(dT)70. This double-
stranded template, which induces a strong XtopBP1-depend-
ent activation of Xatr, elicits a robust phosphorylation of Xchk1
(10, 12). By contrast, a single-stranded template such as (dA)70
does not induce activation of Xatr. The activation of Xchk1 in
the presence of (dA)70-(dT)70 does not require any DNA repli-
cation in egg extracts. We prepared XtopBP1-depleted
extracts, supplemented them with either wild-type or I-II
XtopBP1, and finally added either (dA)70 or (dA)70-(dT)70. As
shown in Fig. 4C, the extract containing wild-type XtopBP1
displayed robust phosphorylation of Xchk1 in the presence of
(dA)70-(dT)70 but not (dA)70. By contrast, addition of (dA)70-
(dT)70 did not induce phosphorylation of Xchk1 in the extract
containing theI-II mutant of XtopBP1. Taken together, these
results indicate that BRCT I-II region of XtopBP1 is essential
for the Xatr-dependent activation of Xchk1 in response to a
number of different checkpoint-inducing DNA templates.
FIGURE 2. The S373Amutant of Xrad9 is compromised in checkpoint sig-
naling. A, Baculoviruses encoding His6-Xrad9, Xhus1, or Xrad1 were used to
coinfect Sf9 insect cells. The complexed recombinant proteins were purified
with nickel-agarose beads. Aliquots of preparations containing wild-type
(lane 2) or S373AmutantHis6-Xrad9 (lane 3)were separatedby SDS-PAGEand
stainedwith Coomassie Brilliant Blue dye. Sizemarkerswere electrophoresed
in lane 1. Note that Xhus1 and Xrad1 have similar electrophoretic mobilities.
B, egg extracts were mock-depleted with control antibodies (lane 1) or immu-
nodepleted with anti-Xhus1 antibodies (lanes 2–4). The extracts were later
supplementedwith buffer alone (lanes 1 and 2), wild-type recombinant 9-1-1
complex (lane 3), or a mutant 9-1-1 complex containing the Xrad9-S373A
protein (lane 4). Extractswere immunoblotted forXhus1, Xrad9, andXtopBP1.
C, the indicated extracts from B were incubated with sperm chromatin and
[35S]Xchk1 in the absence (lane 1) or presence (lanes 2–5) of aphidicolin (APH).
Nuclear fractions were isolated, subjected to SDS-PAGE, and processed for
phosphorimaging todetect labeledXchk1 (top) and for immunoblottingwith
anti-Xrad9 and anti-Xhus1 antibodies (bottom).
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The BRCT I-II Region Regulates Association of XtopBP1 with
Xatr-Xatrip—To investigate the mechanism by which the
BRCT I-II region of XtopBP1 participates in checkpoint regu-
lation, we explored the Xatr-binding properties of the I-II
mutant. Our laboratory recently reported that Xatr-Xatrip dis-
plays increased binding toXtopBP1upon addition of the check-
point-inducing DNA template (dA)70-(dT)70 to egg extracts
(20). To investigate what regions of XtopBP1 contribute to
this regulation, we incubated wild-type or I-II versions of
HF-XtopBP1 in egg extracts containing either (dA)70 or
(dA)70-(dT)70 (Fig. 5A). There was basal binding of wild-type
HF-XtopBP1 to Xatr in the presence of (dA)70. This binding
increased in extracts containing (dA)70-(dT)70. However, we
observed that the I-II mutant of XtopBP1 did not bind
detectably to Xatr in extracts containing either (dA)70 or
(dA)70-(dT)70.
To investigate the generality of these findings, we also used
extracts containing aphidicolin-induced DNA replication
blocks in chromatin. As depicted in Fig. 5B, we could likewise
observe good binding of HF-XtopBP1 to Xatr in nuclei from
aphidicolin-treated extracts. However, there was only very
weak binding of the I-II mutant of
XtopBP1 to Xatr under the same
conditions. Taken together, these
results indicate that the checkpoint-
induced binding of XtopBP1 to Xatr
depends upon the BRCT I-II region
of XtopBP1. This observation is
intriguing because we showed pre-
viously that the AAD of XtopBP1
associates with Xatr-Xatrip (9).
Furthermore, we have been unable
to observe binding of Xatr-Xatrip
to the isolated BRCT I-II domain
of XtopBP1 (data not shown). The
implication is that the BRCT I-II
region regulates the ability of a
distinct region in the protein
(namely, the AAD) to associate
with Xatr-Xatrip.
The Isolated C-terminal Domain
of Xrad9 Acts as a Dominant-nega-
tive Inhibitor of Checkpoint Signal-
ing in Egg Extracts—As another
means to assess the importance of
the interaction between Xrad9 and
XtopBP1, we examined whether the
GST-Xrad9C fragment could act as
an inhibitor of checkpoint signaling
in the egg extract system. For this
purpose, we added either wild-type
or S373A versions of GST-Xrad9C
to aphidicolin-treated extracts and
subsequently examined phospho-
rylation of Xchk1. In these experi-
ments, we monitored phosphoryla-
tion of Xchk1 by immunoblotting
with antibodies specific for phos-
phorylated Ser-344 of Xchk1 (34, 35). Significantly, the wild-
type version of GST-Xrad9C caused a marked reduction in the
phosphorylation ofXchk1 on Ser-344 (Fig. 6A). In addition, this
fragment also caused a large decrease in the phosphorylation of
Claspin on Ser-864, a checkpoint-regulated phosphorylation
that is necessary for binding of Claspin to Xchk1 (36). By con-
trast, the S373Amutant of GST-Xrad9C had little, if any, effect
on the phosphorylation of either Xchk1 or Claspin. The GST-
Xrad9C fragment had no effect on chromosomal DNA replica-
tion in egg extracts (data not shown). To corroborate these
findings further, we used the model DNA template (dA)70-
(dT)70 to induce a checkpoint response. Consistent with the
results described above, wild-type but not S373A GST-Xrad9C
also abolished the phosphorylation of Xchk1 in response to
(dA)70-(dT)70 (Fig. 6B).
To explore how GST-Xrad9C interferes with phosphoryla-
tion of Xchk1, we analyzed whether this fragment might affect
binding of checkpoint proteins to chromatin.We observed that
the wild-type GST-Xrad9C fragment caused a significant
reduction in the binding of endogenous XtopBP1 to aphidico-
lin-treated chromatin (Fig. 6C). Conversely, the S373A mutant
FIGURE 3. The BRCT I-II region of XtopBP1 is necessary and sufficient for binding of Xrad9. A, domain
structure of XtopBP1. B, Xenopus egg extracts were incubatedwith buffer alone (lane 2) or the indicated forms
of XtopBP1 (lanes 3–9). Beads containing anti-FLAGantibodieswere added subsequently. Thebeadswere later
retrieved and processed for immunoblotting with antibodies against the FLAG epitope, Xrad17, Xrad9, and
Xhus1. Lane 1 depicts an aliquot of the initial egg extract. C, extracts were incubated with the indicated forms
of HF-XtopBP1 in the presence (lanes 1 and 3–5) or absence (lane 2) of GST-Xrad9C. Glutathione-agarose beads
were added subsequently. The beads were retrieved and processed for immunoblotting with anti-FLAG anti-
bodies.D, egg extracts were incubatedwith buffer alone (lanes 2 and 6) or fragments of XtopBP1 comprised of
its N-terminal half (lane 3), C-terminal half (lane 4), BRCT domains I-II (lane 7), or BRCT domains III-VI (lane 8).
Anti-FLAG immunoprecipitates were immunoblotted for Xrad17, Xrad9, and Xhus1. Lanes 1 and 5 depict ali-
quots of initial egg extract. E, the indicated fragments of XtopBP1 were subjected to SDS-PAGE directly (lanes
1–4) or incubated in egg extracts (lanes 5–8). Glutathione-agarose beads were added subsequently to the
extracts. The beads were later retrieved and processed for immunoblotting with anti-FLAG antibodies. Arrows
indicate the electrophoretic positions of the N-terminal (top) and BRCT I-II (bottom) fragments of XtopBP1.
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of GST-Xrad9C had no effect on the chromatin-binding prop-
erties of XtopBP1. On the other hand, neither the wild-type nor
S373A forms of GST-Xrad9C appeared to have an effect on
interaction of Xatr with aphidicolin-treated chromatin. These
findings suggest that GST-Xrad9C perturbs the interaction of
XtopBP1 with Xatr-Xatrip at stalled replication forks.
DISCUSSION
In this report, we have explored how the ability of TopBP1 to
activate ATR is regulated during checkpoint responses. The
binding of XtopBP1 to the Xatr-Xatrip complex inXenopus egg
extracts increases in the presence of a checkpoint-triggering
DNA template (20). We have found that an N-terminal region
of XtopBP1 encompassing BRCT repeats I-II is critical for this
regulated binding. This segment of XtopBP1 does not associate
directly with Xatr-Xatrip. Instead, this region is necessary for
Xatr-Xatrip to dock with the AAD of XtopBP1, which is situ-
ated near the other end of the protein between BRCT domains
VI and VII. This process is essential for checkpoint signaling
because egg extracts containing a mutant of XtopBP1 lacking
the BRCT I-II region are completely defective in carrying out
the activation of Xchk1.
In exploring the mechanism by which the BRCT I-II region
contributes to the checkpoint-regulatory function of XtopBP1,
we examined potential binding partners of XtopBP1. Genetic
and biochemical studies in a number of different organisms
have indicated that the 9-1-1 complex and its equivalents inter-
actwithTopBP1 and its homologs (29–31, 37, 38). This binding
involves C-terminal region of the Rad9 protein.We have found
that XtopBP1 interacts strongly with the C-terminal domain of
Xrad9. The BRCT I-II region of XtopBP1 is both necessary and
sufficient for binding to theC-terminal section of Xrad9. About
FIGURE 4.TheBRCT I-II regionof XtopBP1 is essential for thephosphoryl-
ation of Xchk1. A, egg extracts weremock-depleted with control antibodies
(lane 1) or immunodepleted with anti-XtopBP1 antibodies (lanes 2–5).
Extracts were later supplemented with sperm chromatin and buffer alone
(lanes 1 and 2), wild-type HF-XtopBP1 (lane 3), AAD HF-XtopBP1 (lane 4), or
I-II HF-XtopBP1 (lane 5). Extracts were immunoblotted for XtopBP1 and
Xrad17.B, the indicatedextracts fromAwere incubatedwith [35S]Xchk1 in the
absence (lane 1) or presence (lanes 2–5) of aphidicolin. Nuclear fractions from
the extracts were subjected to SDS-PAGE and phosphorimaging. C, mock-
depleted (lanes 1 and 2) andXtopBP1-depleted extracts (lanes 3–8) were sup-
plemented with buffer alone (lanes 1–4), wild-type HF-XtopBP1 (lanes 5 and
6), or I-II HF-XtopBP1 (lanes 7 and 8). The extracts were incubated with
[35S]Xchk1 in the presence of (dA)70 (lanes 1, 3, 5, and 7) or (dA)70-(dT)70 (lanes
2, 4, 6, and 8). Extracts were processed for phosphorimaging.
FIGURE 5. The BRCT I-II region of XtopBP1 is necessary for binding of
Xatr-Xatrip. A, egg extracts (50l) were incubatedwith buffer alone (lanes 2
and 3), wild-type HF-XtopBP1 (lanes 4 and 5), orI-II HF-XtopBP1 (lanes 6 and
7) in the presence of (dA)70 (lanes 2, 4, and 6) or (dA)70-(dT)70 (lanes 3, 5, and 7).
Beads containing anti-FLAG antibodies were added subsequently. Beads
were retrieved and processed for immunoblotting with anti-Xatr and anti-
FLAG antibodies. Lane 1 depicts the content of Xatr in 1 l of egg extract.
B, egg extracts containing added sperm chromatin and aphidicolin were
incubated with either wild-type HF-XtopBP1 (lanes 1 and 3) or I-II
HF-XtopBP1 (lanes 2 and 4). After 60 min, nuclei were isolated by centrifuga-
tion through a sucrose cushion and solubilized as described under “Experi-
mental Procedures.” Nuclear fractions were immunoprecipitated with anti-
FLAG antibodies. Solubilized nuclear fractions (lanes 1 and 2) and anti-FLAG
immunoprecipitates fromnuclear fractions (lanes 3 and 4) were processed for
immunoblotting with anti-FLAG and anti-Xatr antibodies.
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20–40 amino acids from the extreme C-terminal end of Xrad9
are involved in this interaction. Furthermore, this binding
requires phosphorylation of Xrad9 on Ser-373. This interac-
tion is functionally important for checkpoint regulation. For
example, a mutant 9-1-1 complex containing an S373A ver-
sion of the Xrad9 subunit is compromised in checkpoint
signaling. Moreover, a GST fusion protein containing the
C-terminal region of Xrad9 (GST-Xrad9C) is an effective
dominant-negative inhibitor of the activation of Xchk1 in
egg extracts. By contrast, the corresponding S373A mutant
of GST-Xrad9C has no effect on the activation of Xchk1.
Altogether, the results indicate that interaction of Ser-373-
phosphorylated Xrad9 with the BRCT I-II region of XtopBP1
is essential for checkpoint control.
Fission yeast Cut5 and budding yeast Dpb11, the relatives of
TopBP1 in these organisms, interact with Rad9 and its budding
yeast homologue Ddc1, respectively, through C-terminal
regions containing BRCT repeats III-IV (30, 37). This finding
apparently contrasts with our observation that the N-terminal
BRCT I-II region of XtopBP1 associates with Xrad9. However,
the yeast proteins are considerably smaller than vertebrate
TopBP1 and possess only four BRCT repeats, as opposed to
eight in the vertebrate proteins. Furthermore, the AAD is not
obviously conserved in fission yeast Cut5 and budding yeast
Dpb11. Indeed, the AAD appears to be strongly conserved only
in vertebrates. In general, it appears that the yeast and verte-
brate versions of TopBP1 are similar in that they are involved in
bothDNA replication and checkpoint control (7). Nonetheless,
there are substantial structural differences between the yeast
and vertebrate forms of these proteins.
In a previous study, Ma¨kiniemi et al. (38) found in yeast two-
hybrid experiments that human TopBP1 interacts with human
Rad9 through BRCT repeats IV-V. However, these authors did
not carry out studies in human cells or biochemical experi-
ments to establish that BRCT IV-V was either necessary or
sufficient for binding of Rad9. Furthermore, these investigators
did not examinewhether this regionwas involved in checkpoint
regulation. Overall, we believe that we have provided convinc-
ing evidence that the BRCT I-II region of XtopBP1 mediates a
functionally important interaction with Xrad9 in the egg-ex-
tract system.
In human cells, Ser-387 of Rad9 (the equivalent of Ser-373 in
Xrad9) is constitutively phosphorylated during the cell cycle
(29). Therefore, phosphorylation of this residue does not
require the presence of DNA damage or stalled DNA replica-
tion forks. Consistent with this observation, we have found that
GST-Xrad9C can associate with endogenous XtopBP1 in inter-
phase egg extracts even in the absence of a checkpoint-inducing
DNA template. This type of apparently constitutive process
would allow the XtopBP1-Xrad9 complex to function at a very
early step in the initiation of checkpoint signaling. Because this
binding would not be dependent on regulation by an upstream
checkpoint-signaling kinase, this complex could respond
directly to checkpoint-triggering signals in the genome. Inter-
estingly, the sequences around Ser-387 and Ser-373 in human
Rad9 andXrad9, respectively, resemble the consensus for phos-
phorylation by casein kinase 2, which is constitutively active
throughout the cell cycle (39).
FIGURE 6. TheGST-Xrad9 fragment containing residues 258–377 interferes
with phosphorylation of Xchk1. A, egg extracts containing sperm chromatin
wereincubatedwithbufferalone(lanes1and2),wild-typeGST-Xrad9C(lane3),or
S373A GST-Xrad9C (lane 4) in the absence (lane 1) or presence (lanes 2–4) of
aphidicolin. Nuclear fractions were isolated and processed for immunoblotting
with antibodies against GST, phospho-Ser-344 of Xchk1, Xchk1 protein, phos-
pho-Ser-864ofClaspin,Claspinprotein,andXtopBP1as indicated.B, eggextracts
withadded[35S]Xchk1were incubatedwithbufferalone(lanes1and2),wild-type
GST-Xrad9C(lane3),orS373AGST-Xrad9C(lane4)versions intheabsence(lane1)
or presence (lanes 2–4) of (dA)70-(dT)70. Samples were subjected to SDS-PAGE
and phosphorimaging. C, chromatin fractions from the indicated samples in A
were immunoblotted for bound XtopBP1, Xatr, and Xorc2.
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The 9-1-1 complex is thought to recognize recessed DNA
ends that would abut regions of single-stranded DNA at rep-
lication forks and sites of damages (17–19, 40). Single-
stranded DNA, which is coated with replication protein A,
attracts the binding of inactive ATR-ATRIP in various sys-
tems (12, 41, 42). Subsequently, Xatr-Xatrip undergoes acti-
vation upon binding of XtopBP1 (9, 21, 22). Interaction of
XtopBP1 with the 9-1-1 complex may allow XtopBP1 to acti-
vate Xatr-Xatrip when both recessed DNA ends and single-
stranded DNA are present (Fig. 7).
In principle, binding of the 9-1-1 complex to XtopBP1 could
be involved in the activation ofXatr or the recognition of down-
stream substrates by Xatr or both. Our findings are most con-
sistent with a role for 9-1-1 in the events leading to the forma-
tion of fully activated Xatr. First, 9-1-1 interacts well with the
established direct activator of Xatr, namely XtopBP1. Second,
9-1-1 associateswith the region ofXtopBP1 (i.e.BRCT I-II) that
is necessary for both binding and activation of Xatr. Finally, the
isolated C-terminal domain of Rad9 acts as a dominant-nega-
tive inhibitor that blocks binding of Xatr to XtopBP1 and hence
forestalls activation of Xatr.
It is possible that, in addition to localizing XtopBP1 near Xatr-
Xatrip, the 9-1-1 complex may also trigger structural changes in
XtopBP1 that would allow interaction with Xatr-Xatrip. We sus-
pect that XtopBP1 may exist in a repressed form that would be
incapable of activating Xatr inappropriately in the absence of a
checkpoint-triggering signal. Interaction of the BRCT I-II region
of XtopBP1 with the 9-1-1 complex on a checkpoint-triggering
DNA structure may alleviate this repressed state.
The situation appears to be somewhat different in budding
yeast. Majka et al. (43) presented evidence that a recombi-
nant version of the 9-1-1 complex from this organism (Ddc1-
Mec3-Rad17) could activate Mec1-Ddc2 (ATR-ATRIP)
directly in vitro. By contrast, the Xenopus 9-1-1 complex
recruits XtopBP1, apparently the most proximal activator of
Xatr-Xatrip.
The exact roles of fission yeast Cut5 and budding yeast
Dpb11 in checkpoint activation are not clear. Because these
proteins appear to lack an obvious AAD, they may not interact
with ATR in the samemanner as TopBP1. However, Cut5 does
associate with Rad3 (ATR) in fission yeast during checkpoint
responses (30). Interestingly, this interaction requires phos-
phorylation of Rad9 on T412. Moreover, checkpoint-regulated
phosphorylation of both Cut5 and Crb2 is dependent upon the
Thr-412 site inRad9.Thus, it appears that Rad9 regulates Rad3-
dependent signaling in this system. Further study of how
XtopBP1 and Cut5/Dpb11 respond to DNA structures should
provide additional insight into the earliest steps in checkpoint-
signaling pathways.
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